INcentives and ReMINDers to Improve Long-term Medication Adherence (INMIND)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorRAND
About this trial
Low medication adherence when initiating antiretroviral treatment (ART) is a key barrier to HIV virologic suppression, resulting in avoidable cases of drug resistance, death, and viral transmission. Routinized pill-taking can lead to successful long-term ART adherence, and short-term behavioral economics-based supports are a novel way to overcome the limited success of existing routinization interventions. This study proposes to test this combined approach for promoting long-term ART adherence using a Stage III Sequential, Multiple Assignment, Randomized Trial (SMART) design in one of the largest HIV clinics in Uganda to identify the most cost-effective adaptive intervention that if found effective is generalizable to other settings and other chronic diseases.
Eligibility criteria
Qualifiers
Male and female clients age 18 and older.
Started ART at Mildmay or another clinic within the preceding 2 months
Able to speak and understand either English or Luganda.
Have their own cell phone or have consistent access to someone else's phone.
Disqualifiers
Not mentally fit to consent.
Language other than Luganda or English.
Not willing to consistently use the Wisepill device for adherence measurement.
Trial design
Treatments tested in this trial
- Daily Text Messages
- Incentivization based on timely ART adherence
Treatment groups
550 Participants
are divided into 4 treatment groupsSponsors and collaborators
RAND
Lead sponsor
Arizona State University
Collaborator
National Institute of Mental Health (NIMH)
Collaborator
Mildmay Uganda Limited
Collaborator
Source ClinicalTrials.gov